MT2019-40: A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination withRituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and ChronicLymphocytic Leukemia

Project: Research project

Project Details

Description

MT2019-40: A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
StatusActive
Effective start/end date10/18/1910/31/24

Funding

  • Fate Therapeutics, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.